Namibia - English - Namibia Medicines Regulatory Council

pfizer laboratories (pty) ltd - vincristine sulphate - injection - vincristine sulphate injection 1mg/ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

pfizer australia pty ltd - sulfato de vincristina - sulfato de vincristina....1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - this medicine is indicated in certain diseases of the blood and in certain tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in the treatment of acute leukemia. it has also been used in combination with other antineoplastic drugs in hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of the uterine cervix, malignant melanoma, colorectal cancer, non-hodgkin's lymphoma, and wilm's tumor. the simultaneous use of several cancer chemotherapy drugs is common practice. generally drugs with different dose limiting clinical toxicities and different mechanisms of action are selected in order to obtain an increase in therapeutic response without added toxicity. rarely is it possible to obtain euqlly as good response with single antineoplastic agent treatment. therefore, vincristine is often part of polychemotherapy because at the recommended doses it does not cause a significant suppression of bone marrow or neuropathy. in children multiple-agent chemotherapy of malignant disease is also common. vincristine should be considered for use with other oncolytic agents in the treatment of neuroplastoma, ostoegenic sarcoma, ewing's sarcoma, rhabdomyosarcoma, wilm's tumor, hodgkin's diseases, non-hodgkin's lymphomas, embryonal carcinoma of the ovaries and rhabdomyosarcoma of the uterus. although not recommended as a primary treatment, vincristine may be useful in the treatment of true idiopathic thrombocytopenia purpura which has shown to be refractory to splenectomy and treatment with steroids. administration of the recommended dose of vincristine weekly for 3 to 4 weeks has resulted in permanent remission in some patients. however, if no response is obtained after 3 to 6 doses it is unlikely that there will be any beneficial effects with additional administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - acute leukaemia. combined therapy in hodgkin?s disease, non-hodgkin lymphoma, including special forms of these condition, rhabdomyosarcoma, neuroblastoma, wilm?s tumour, osteosarcoma, ewing?s sarcoma, malignant melanoma, small-cell carcinoma of the lung, gynaecological tumours of childhood, carcinoma of the breast. idiopathic thrombocytopenic purpura (werlhof?s disease) in patients who have not responded to a splenectomy and short-term treatment with corticosteroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - acute leukaemia. in combination with other cytostatic drugs for hodgkin's disease, lymphosarcoma, reticulocyte sarcoma, rhabdomyosarcoma, neuroblastoma, and wilms' tumour.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - acute leukaemia. combined therapy in hodgkin?s disease, non-hodgkin lymphoma, including special forms of these condition, rhabdomyosarcoma, neuroblastoma, wilm?s tumour, osteosarcoma, ewing?s sarcoma, malignant melanoma, small-cell carcinoma of the lung, gynaecological tumours of childhood, carcinoma of the breast. idiopathic thrombocytopenic purpura (werlhof?s disease) in patients who have not responded to a splenectomy and short-term treatment with corticosteroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - ? acute leukemia. ? the treatment of hodgkin's disease, lymphoma ? malignant non-hodgkin's, (types, mixed-cell, histiocytic, undifferentiated, nodular lymphocytic and diffuse) ? rhabdomyosarcoma ? neuroblastoma ? wilms tumour ? osteogenic sarcoma ? mycosis fungoides, ? ewing's sarcoma ? breast cancer ? malignant melanoma ? small cell lung cancer ? gynecological tumors of childhood. true idiopathic thrombocytopenic purpura, refractory to splenectomy and to short-term treatment with adrenocortical steroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; mannitol; sulfuric acid - vincristine sulfate is indicated in acute leukemia. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. in recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. paediatric patients with neuroblastoma, osteogenic sarcoma, ewing?s sarcoma, rhabdomyosarcoma, wilm?s tumour, hodgkin?s disease, non-hodgkin?s lymphomas, embryonal carcinoma of the ovaries, and rhabdommyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. close co-operation among oncologists, paediatricians, radiologists and surgeons is required in order to achieve the best possible results. patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine sulphate, but the drug is not recommended as primary treatment for this disorder.